Top Ten most popular articles on Pharmafile.com this week!
pharmafile | February 15, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | AMR, Dame Sally Davies, FDA, FMD, antibiotic resistance, esketamine, falsified medicines, top 10
News that the FDA’s advisory panel had recommended Janssen’s intranasal esketamine spray Spravato as a treatment for treatment resistant depression, took the top spot this week. The therapy, based on party drug ketamine, may act as a significant breakthrough in the neglected area of mental health.
Other news saw England’s chief medical officer Dame Sally Davies, who is leaving her current role to become Master of trinity College Cambridge, suggest that as many as one third of antibiotics may be prescribed inappropriately.
Meanwhile as the Falsified Medicines Came into effect the ABPI warned that a no-deal Berxit could lead to it being scrapped in the UK. Check out this week’s top ten most popular stories of this week!
One third of the antibiotics prescribed by the NHS are given out despite there being no medical evidence that they are necessary, England’s Chief Medical Officer Dame Sally Davies has said.
9. First asthma pill in two decades could treat condition by reducing airway muscle
Researchers at the University of Leicester alongside colleagues in Vancouver, Canada, have revealed data that supports the efficacy of an investigational pill for the treatment of asthma. The oral, selective prostaglandin D2 receptor antagonist, known as Fevipiprant, is the first of its kind for two decades.
8. Researchers develop new, more effective method for detection of HIV virus genomes
A team of researchers have devised a new way to accurately detect residual HIV in the body’s immune cells, allowing for better evaluation of the efficacy of potential therapies in eliminating the active form of the virus.
7. Sanofi name current CMO Dr Ameet Nathwani as new Chief Digital Officer
French firm Sanofi has appointed pharma veteran Dr Ameet Nathwani to the position of Chief Digital Officer.
6. FMD would not apply in case of no-deal Brexit
The Falsified Medicines Directive would be scrapped in the event of a no deal Brexit, the Association of the British Pharmaceutical Industry (ABPI) has warned. The scrapping of the EU legislation could put patients at risk.
5. GSK buys Merck KGaA’s cancer immunotherapy for $4.2 billion
British multinational GlaxoSmithKline has agreed to pay up to €3.7 billion ($4.2 billion) for the rights to Merck KGaA’s next generation cancer immunotherapy.
4. Gilead’s CAR-T therapy Yescarta rejected for NHS use in Scotland
It’s bad news for Scottish patients living with aggressive forms of non-Hodgkin lymphoma (NHL) as it emerges that the Scottish Medicines Consortium has chosen to reject Gilead’s CAR-T therapy Yescarta (axicabtagene ciloleucel).
3. Researchers find new type of cell membrane which causes cancer cells to explode
Researchers at the Medical University of South Carolina (MUSC) have discovered a new type of cell membrane complex which causes cells to explode. The cell membrane complexes may be a useful target for those developing drugs that kill cancer cells.
2. Feature: Solving the drug development problem
Excitement is building for the potential of AI in just about every field, but how can it address pharma’s unique challenges? Matt Fellows speaks to the not-for-profit organisation the Pistoia Alliance to see where the industry identifies these challenges, and how the technology can help tackle them.
1. Janssen’s esketamine drug recommended by FDA panel for depression
Janssen has announced that its esketamine nasal spray Spravato has been recommended by the FDA’s advisory panel for the treatment of treatment-resistant depression.
Related Content
Johnson & Johnson submits robotic surgical system for De Novo classification
Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …
MedPharm announces US FDA inspection of North Carolina manufacturing facility
MedPharm has announced that the US Food and Drug Administration (FDA) has completed a successful …
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
